Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.52 |
| ▸ | IDH1 | O75874 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | EIF4E | P06730 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3815644 | 0.84 | RAB9A (0.54) | RAB9AKDM4ESMN1; SMN2LMNACYP19A1 | |
| SCHEMBL3814593 | 0.77 | KDM4E (0.66) | RAB9AKDM4ESMN1; SMN2LMNACYP19A1 | |
| SCHEMBL3813712 | 0.77 | KDM4E (0.69) | RAB9AKDM4ESMN1; SMN2LMNACYP19A1 | |
| SCHEMBL6646406 | 0.77 | KDM4E (0.61) | RAB9AKDM4ESMN1; SMN2LMNACYP19A1 | |
| SCHEMBL3824243 | 0.75 | KDM4E (0.58) | RAB9AKDM4ESMN1; SMN2LMNACYP19A1 | |
| SCHEMBL3821664 | 0.75 | EIF4E (0.44) | RAB9AKDM4EGRM1NPC1EIF4E | |
| SCHEMBL12467643 | 0.74 | RAB9A (0.59) | RAB9AKDM4ESMN1; SMN2LMNAGRM1 | |
| SCHEMBL6627488 | 0.74 | KDM4E (0.61) | RAB9AKDM4ESMN1; SMN2LMNACYP19A1 | |
| SCHEMBL6647162 | 0.74 | KDM4E (0.61) | RAB9AKDM4ESMN1; SMN2LMNACYP19A1 | |
| SCHEMBL6647164 | 0.73 | KDM4E (0.59) | RAB9AKDM4ESMN1; SMN2LMNACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1348706-B1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-08-19 | — | — | EP | disclosed |
| US-7067537-B2 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-27 | — | — | US | disclosed |
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1348706-A1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | CYP17A1, CYP21A2, HSD17B1 | RAB9A 4836/4885KDM4E 1126/4885SMN1; SMN2 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.